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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is an interstitial fibrotic lung disease of unknown origin and
without effective therapy characterized by deposition of extracellular matrix by activated fibroblasts in the lung.
Fibroblast activation in IPF is associated with Wnt/β-catenin signaling, but little is known about the role of the
β-catenin-homologous desmosomal protein, plakoglobin (PG), in IPF. The objective of this study was to assess the
functional role of PG in human lung fibroblasts in IPF.
Methods: Human lung fibroblasts from normal or IPF patients were transfected with siRNA targeting PG and used
to assess cellular adhesion to a fibronectin substrate, apoptosis and proliferation. Statistical analysis was performed
using Student’s t-test with Mann–Whitney post-hoc analyses and results were considered significant when p < 0.05.
Results: We found that IPF lung fibroblasts expressed less PG protein than control fibroblasts, but that characteristic
fibroblast phenotypes (adhesion, proliferation, and apoptosis) were not controlled by PG expression. Consistent with
this, normal fibroblasts in which PG was silenced displayed no change in functional phenotype.
Conclusions: We conclude that diminished PG levels in IPF lung fibroblasts do not directly affect certain phenotypic
behaviors. Further study is needed to identify the functional consequences of decreased PG in these cells.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic progres-
sive fibrotic disorder of the lung with no clear etiology
[1] and without proven therapies to impact mortality.
Alveolar epithelial cell injury may be an initiating factor
in fibrotic lung repair, which might reflect an aberrant
recapitulation of developmental programs as a means to
repair the injured tissue [2]. With this in mind, recent
work has begun to evaluate the role of cellular adhesion
proteins as mediators responsible for the progression of
IPF [3], with both junctional and non-junctional properties
being investigated. As an example, the Wnt pathway is typ-
ically activated during development, but is thought to be-
come re-activated in IPF as an epithelial repair response
[3–7]. Experimental evidence suggests that blockade of this
pathway may in fact attenuate the fibrotic response in
experimental models [8–10].
Desmosomes are intercellular junctions that provide
adhesion and tensile strength to tissues by anchoring
intermediate filaments to the cell surface [11, 12].
Desmosomes are instrumental in providing and main-
taining stability to tissues under high mechanical strain
while also serving as orchestrators of signaling molecules.
Plakoglobin is an Armadillo-repeat protein that is highly
homologous to β-catenin and functions as a junctional
protein in the desmosome. In light of its homology with
β-catenin, PG has previously been shown to regulate Wnt
signaling [13, 14]. However, it is also clear that PG plays a
so-called ‘non-junctional’ role other than providing inter-
cellular adhesion and strength to opposing cells. Despite
evidence suggesting that non-junctional roles of PG may
be important in regulating cell biology, no studies to date
have examined these properties in fibrotic pulmonary
mesenchymal cells.
One of the hallmarks of IPF is injury to the alveolar
epithelial cells and subsequent recruitment of fibroblasts
and myofibroblasts. Myofibroblasts are differentiated fibro-
blasts that express α-smooth muscle actin in organized
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stress fibers that confer the differentiated cell with contract-
ile properties similar to smooth muscle. This contraction,
along with the synthesis of extracellular matrix, positions
the myofibroblast as a critical effector cell in the wound-
repair response [15]. Neighboring myofibroblasts commu-
nicate through mechanical adhesion structures such as the
adherens junction (AJ), which contain single-pass trans-
membrane cadherins, p120-catenin, β-catenin, and PG
proteins that bind to α-actinin and subsequently actin
filaments [16].
Fibronectin (Fn) is a fibrillar multimeric protein that
serves as an integral linker protein which strengthens
and stabilizes the extracellular matrix [17]. Cross-talk
between cell-cell and cell-matrix adhesion, in particular
between PG and Fn have been shown in PG−/− keratino-
cytes where cell motility, focal adhesions and Fn (Fn1)
mRNA stability were altered [18].
To determine whether PG affects the physiological be-
havior of pulmonary fibroblasts, we examined the adhe-
sive properties of fibroblasts to a cellular fibronectin




Primary lung fibroblasts were explanted from human
distal lung as previously described [19]. Normal fibro-
blasts were isolated from organ donors whose lungs were
deemed unsuitable for transplantation. IPF fibroblasts were
isolated from lungs of patients at time of transplantation.
Lung samples were obtained from Gift of Life Michigan
and the use of tissues was pre-approved by Gift of Life
Michigan. The University of Michigan Institutional Review
Board has reviewed this protocol and deemed it exempt
from oversight as all samples were completely de-identified
prior to acquisition. All cells were used between passages 2
and 9, and were maintained in Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 10 % fetal bovine
serum, 10 mM HEPES, 100 U/mL penicillin, 100 U/ml
streptomycin, and 2.5 mg/L Amphotericin B.
siRNA-mediated knockdown of plakoglobin (PG)
PG was silenced in primary lung fibroblasts using stealth
RNAi™ from Invitrogen (Life Technologies, Grand Island,
NY). The siRNA-PG sequence was: 5′-UCAAGUCGGC-
CAUUGUGCAUCUCAU-3′. The non-targeting control
construct (ΦsiRNA-PG) used in all control experiments
contained the following sequence: 5′-AUGCUGAGUACA-
CUAACGGAGCUGA-3′. Transfection was carried out
using Lipofectamine RNAi™Max (Invitrogen) and serum
free media. After 24 hours, media with 3 % fetal bovine
serum was added and used in the experiments described
below 72 hours post-transfection.
Semi-Quantitative Real Time Polymerase Chain Reaction
(SQ RT-PCR)
SQ RT-PCR was used to quantify endogenous levels of
plakoglobin in whole lung tissue (jup: Fwd: CCGAGGA-
CAAGAACCCAGAC, REV: GTGGCATCCATGTCAT-
CTCC) and GAPDH (FWD: GTC TTC ACT ACC ATG
GAG AAG G, Rev: TCATGGATGACCTTGGCCAG) as
previously described [20, 21]. Primers were designed using
the NCBI/Primer-Blast tool and the comparative cycle
threshold approach was used to determine relative gene
expression patterns [22]. The relative expression level of
the gene (ΔCt) was calculated as follows: Ct JUP-Ct GAPDH,
and the relative expression level of jup was calculated using
the 2-ΔΔCt method.
Western blots
Western blots were performed as previously described
[19, 21]. Primary antibodies include GAPDH (Cell Sig-
naling Technology, 1:1000), poly ADP ribose polymerase
(PARP) (Cell Signaling Technology, 1:1000) and PG (BD
Transduction Laboratories, 0.25 μg/mL). Secondary anti-
bodies (ThermoFisher Scientific) included anti-mouse IgG
HRP (for PG) or anti-rabbit IgG HRP (for GAPDH and
PARP). GAPDH was used as a loading control for all
primary antibodies. Bands were developed using Super-
Signal® West Pico Chemiluminescent Substrate (Thermo-
Fisher Scientific).
Adhesion assays
A 96-well assay plate (Corning Incorporated, Costar®)
was coated with either cellular fibronectin (cFN) at
20 μg/mL or left uncoated for the bovine serum albumin
(BSA) control and incubated overnight at 4 °C. Plates
were subsequently washed with PBS to remove unbound
cFN and blocked for 30 minutes at 37 °C with 1 % BSA
in serum-free DMEM. Cells were rinsed with Hanks’
Balanced Salt Solution (HBSS) without magnesium or
calcium chloride (Gibco, Life Technologies) and har-
vested using 2 mM EDTA. Following detachment, HBSS
containing both magnesium and calcium chloride was
added in equal volume to the EDTA solution. Cells were
centrifuged at 318 × g and the pellet was re-suspended
in serum-free DMEM. Cells were counted, seeded at a
density of 50,000 cells/well, then centrifuged at 8 × g
and incubated at 37 °C and 5 % CO2 for one hour.
Plates were then centrifuged inverted for 5 minutes at
50 × g to remove unattached cells. Remaining cells were
fixed at room temperature with 0.5 crystal violet, 1 for-
maldehyde and 20 % methanol in double-distilled
water. The plate was rinsed with PBS and fluorescence
emission was measured in a microplate reader (Spectra-
Max M5 microplate reader, Molecular Devices, Sunny-
vale, CA) at 595 nm.
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Apoptosis assay
Apoptosis was induced in serum-starved fibroblasts by
treating with anti-FasL antibody (human, activating;
Millipore (Billerica, MA), 0.5 μL/mL) alone or in con-
junction with cycloheximide (Sigma-Aldrich, 1 μL/mL) for
6 hours or overnight. Cell lysates were harvested and
assayed for cleavage of PARP by immunoblot as described
[23] or processed for flow cytometry using Annexin V and
propidium iodide (Alexa Fluor® 488 Annexin V/Dead Cell
Apoptosis Kit, Life Technologies). Samples prepared for
flow cytometry according to manufacturer’s protocol were
immediately processed on a MoFlow Astrios™ cell sorter
(Beckman Coulter, Brea, CA) [24].
Proliferation assays
Dishes were coated with cell-derived fibronectin (purified
from conditioned media of human lung fibroblasts; 20 μg/
ml) then rinsed and blocked as described above. Cells were
seeded at 5000 cells/well in triplicate wells per condition
and incubated with 1 % serum+DMEM in addition to
20 ng/mL of Platelet Derived Growth Factor (PDGF, R&D
systems, Minneapolis, MN) or 2 ng/mL of human recom-
binant TGF-β1 (R&D systems, Minneapolis, MN). The cells
were then incubated at 37 °C and 5 % CO2 for 24 hours.
Proliferation was assessed using the CyQuant® NF Cell
Proliferation assay (Life Technologies) following the manu-
facturer’s instructions. Fluorescence intensity was measured
with a microplate reader. Blank wells containing dye only
and background (cells, no dye) were subtracted from the
average emission of three wells for each condition.
Statistical analysis
All experiments were analyzed using GraphPad Prism
6.02 (La Jolla, CA). Results were considered significant
when p < 0.05 using the nonparametric Mann–Whitney
U test. All results were reported using the mean ± SEM.
Results
Plakoglobin expression in normal and IPF lung fibroblasts
Because of the potential role for plakoglobin in mediat-
ing Wnt/β-catenin activity, we first sought to evaluate
the RNA and protein expression of plakoglobin in pri-
mary lung fibroblasts from normal controls or IPF pa-
tients. The RNA expression profile for plakoglobin was
not significantly different between normal (n = 7) and
IPF patients (n = 8) (Fig. 1); however protein expression
levels of plakoglobin did appear to be significantly lower
in IPF whole lung homogenates (n = 5) compared to nor-
mal whole lung homogenates (n = 6), suggesting possible
increased turnover or decreased protein translation. PG
protein levels in explanted fibroblasts demonstrated het-
erogeneity within both the normal and IPF populations
(Fig. 2a). Despite this heterogeneity, densitometric ana-
lysis revealed a small but statistically significant decrease
in plakoglobin expression from the IPF fibroblast popu-
lation in comparison to the control cells (Fig. 2b, Nor-
mal, n = 46 and IPF, n = 31, p = 0.05).
Loss of Plakoglobin does not impact fibroblast adhesion,
proliferation, or apoptosis
To determine whether a reduction in plakoglobin was
associated with functional consequences, we used siRNA
to silence it using in primary normal lung fibroblasts.
Figure 3, demonstrates the near-complete knockdown of
plakoglobin in cells transfected with the specific siRNA
(siRNA-PG). As expected the control siRNA (φ-siRNA)
had no significant impact on PG expression in these
normal lung fibroblasts.
Fig. 1 Plakoglobin (PG) RNA and protein expression levels between normal and IPF whole lung. Each normal (white, n = 7) or IPF (black, n = 8)
whole lung lysate was assessed for PG RNA expression by RT-PCR and shown in a grouped based on classification. Relative change in PG (jup)
expression was obtained by comparing PG to GAPDH. PG transcript levels in IPF lungs showed a trend toward increased expression, but were not
statistically significantly different from normal fibroblasts (a). Normal (white, n = 6) or IPF (black, n = 5) whole lung lysates were assessed for PG
protein expression by western blot. There is a significant decrease in PG protein expression in IPF lung tissue compared to the normal lung tissue
(b, p = 0.04)
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In pulmonary fibrosis, fibroblasts and myofibroblasts
accumulate in fibronectin- and collagen-rich structures
termed fibroblastic foci [19]. Since plakoglobin plays a role
in cell-cell adhesion, we sought to determine whether we
could also identify such a role for plakoglobin in cell-
matrix adhesion. Figure 4c demonstrates that there was
no significant difference in normal or IPF fibroblasts that
were transfected with siRNA-PG or with a control siRNA,
Φ-siRNA and seeded on a fibronectin-coated dish (Nor-
mal Φ-siRNA and siRNA-PG, n = 17 and IPF Φ-siRNA
and siRNA-PG, n = 14). Notably, there was no significant
difference in adhesion between normal and IPF fibro-
blasts. These data suggest that cell-fibronectin adhesion is
independent of plakoglobin. To demonstrate sufficient cell
adhesion untreated normal fibroblasts were seeded on
cellular fibronectin coated tissue culture plastic or tissue
culture plastic only (TCPO)(Fig. 4a). As expected, cells
adhered robustly to cellular fibronectin coated wells com-
pared to the TCPO condition. To further validate the
efficacy of our adhesion experiments, cellular fibronectin
coated wells were treated with a RGD peptide known for
blocking the RGD sequence responsible for adhesion in
cellular fibronectin [25, 26]. As expected the RGD peptide
blocked fibroblast adhesion to cellular fibronectin (Fig. 4b).
To assess whether plakoglobin influences fibroblast
proliferation, we next seeded cells in a FN-coated 96-
well dish. Cells were then transfected with siRNA con-
structs and serum-starved for 48 hours, followed by a
24-hour incubation in 1 % serum-containing media with
or without stimulation by PDGF (Fig. 5a) or TGF-β (data
not shown). A BSA control was used on normal control
transfected fibroblasts to ensure proper induction of
proliferation following transfection. The BSA control group
(n = 16) had a significantly lower rate of proliferation com-
pared to all of the PDGF-treated experimental groups.
These include the normal ΦsiRNA (n = 6, p < 0.01), normal
siRNA-PG (n = 6, p < 0.05), IPF Φ-siRNA (n = 6, p < 0.002)
and IPF siRNA-PG (n = 6, p < 0.03) (Fig. 5a). A baseline of
Fig. 2 IPF pulmonary fibroblasts have reduced level of PG protein expression. Each normal (white) or IPF (black) cell line was assessed for PG
protein expression by Western blot and shown as individual protein expression in (a) or grouped based on classification (b). The individual cell
line levels (left panel) are normalized to S127N. Densitometric ratios were obtained by comparing PG to GAPDH. b When the cells are grouped
the IPF cells overall show a significant decrease in PG expression compared to normal cells (Normal, n = 46 and IPF, n = 31, p < 0.05)
Fig. 3 Successful knockdown of PG in lung fibroblasts. Treatment of lung fibroblasts with siRNA-PG dramatically reduces cellular PG protein
expression as shown in a western blot (a). On average the cells treated with siRNA-PG achieved a significant reduction ~79 % efficient knockdown
of PG protein (****p < .0001) (b)
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Fig. 5 PG expression does not affect proliferation in normal or IPF fibroblasts. The rate of proliferation remained unchanged in both normal and
IPF fibroblasts following PG knockdown. Normal cells transfected with ɸsiRNA were cultured in BSA ( n = 16) and had a significant reduction in
proliferation compared to all other experimental groups stimulated with PDGF which include normal Φ-siRNA (n = 6, p < 0.01), normal siRNA-PG
(n = 6, p < 0.05), IPF Φ-siRNA (n = 6, p < 0.002) and IPF siRNA-PG (n = 6, p < 0.03) (a). Both normal and IPF cells treated with either ɸsiRNA or siRNA-PG
were also kept in 1 % FBS (b) as a control. There were no significant differences in proliferation observed with the PDGF or 1 % FBS treatments groups.
Notably, IPF lung fibroblasts were observed to proliferate to a similar degree as normal cells
Fig. 4 PG expression does not significantly alter cellular adhesion to fibronectin. Cell adhesion assays using cellular fibronectin (cFn) or tissue culture
plastic (TCPO) served as a substrate for normal fibroblasts. The cells seeded on cFn had a 6-fold increase in adherence compared to TCPO (p < 0.0001 )
(a). To ensure cFN has been serving as a proper adhesion substrate, untreated normal cells were treated with an RGD peptide to block the adhesive
properties of cFn. Those cells treated with the peptide had 4.5 fold less adhesion compared to the cFN only cells (p < 0.02) (b). Normal (n = 17) or IPF
cells (n = 14) transfected with either Φ-siRNA or siRNA-PG and placed on the cFn substrate showed no difference in adhesive capacity to fibronectin (c)
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proliferation was obtained in Fig. 5b using 1 % serum-
containing only media without the stimulation of PDGF or
TGF-β. Silencing plakoglobin had no significant impact on
the proliferation of either normal or IPF fibroblasts stimu-
lated with serum or PDGF. Although IPF fibroblasts treated
with siRNA-PG had a slight decrease in proliferation, there
were no significant differences between PG-silenced normal
or IPF fibroblasts.
One hallmark of IPF is the presence of relatively apop-
tosis-resistant fibroblasts [27, 28]. Since prior data suggests
a role for plakoglobin in mediating apoptosis [29, 30], we
next transfected primary normal or IPF fibroblasts with
siRNA-PG or ΦsiRNA constructs followed by induction of
apoptosis using a Fas-activating antibody and cyclohexi-
mide for 6 hours (N = 16 for both normal and IPF cells
transfected with either ΦsiRNA or siRNA-PG) [23, 27, 31].
A representative western blot of IPF fibroblasts that have
been successfully silenced and probed for cleaved PARP
expression is shown in Fig. 6. The normal fibroblasts were
treated and assessed in the same manner (data not shown).
As predicted, and consistent with Fig. 6, we observed a
significant induction of apoptosis in cells treated with the
combination of anti-FasL and Cycloheximide (+/+), as indi-
cated by the level of cleaved PARP (89/116 kDa) expres-
sion relative to GAPDH after 6 hours of treatment (Fig. 7
panels a and b, normal ΦsiRNA (+/+) vs. normal ΦsiRNA
(−/−) p < 0.0003, normal siRNA-PG (+/+) vs. normal
siRNA-PG (−/−), p < 0.0002, IPF ΦsiRNA (+/+) vs. IPF
ΦsiRNA (−/−) and IPF siRNA, p < 0.01, respectively). Not-
ably, silencing plakoglobin did not appear to enhance
apoptosis in IPF fibroblasts treated with the combination
of Fas-activating antibody and cycloheximide (Fig. 7 panel
b, p <0.01). To assess cell viability in normal and IPF fibro-
blasts after 6 hours of treatment with or without siRNA-
PG and anti-FasL/Cycloheximide, cells were stained for
propidium iodide (PI) and analyzed through flow cytome-
try. Silencing PG led to no significant difference in cell
death in normal (7C) or IPF (7D) fibroblasts as indicated
by PI staining (Fig. 7, panels c and d).
Discussion
Due to both the importance of normal plakoglobin ex-
pression and the high level of homology between plako-
globin and β-catenin, there have been great efforts
towards characterizing the role that plakoglobin may
play in the Wnt/β-catenin pathway. Our data suggest
that critical fibroblast functions in IPF are not regulated
by the presence of plakoglobin.
A challenge in studying IPF is the heterogeneity of the
disease across a wide spectrum of patients [32–34]. This
heterogeneity results in seemingly non-significant trends
in biochemical analysis across several samples as exem-
plified in the plakoglobin protein expression profiles
shown in Fig. 2. Despite this difference there is still a
significant reduction in overall plakoglobin protein de-
tected in IPF samples versus normal fibroblasts. The
RNA levels between the normal and IPF lung tissue re-
mains non-significant, which suggests that plakoglobin
may undergo alternative splicing and/or other post-
translational modifications. Since other studies have
shown that a reduction in plakoglobin leads to aberrant
cellular processes including adhesion [35], proliferation
[36] and apoptosis [37], we examined these physiological
processes in normal and IPF lung fibroblasts.
Cell-matrix interactions are thought to drive fibroblast
phenotypic behaviors in IPF [21, 38]. Thus, we hypothe-
sized that silencing plakoglobin might affect cellular adhe-
sion to fibronectin, a major protein found in fibroblastic
foci in IPF [20, 39]. Even though we did not identify a
significant difference in matrix adhesion before or after
plakoglobin silencing (Fig. 4c), we cannot exclude the pos-
sibility that other, non-fibronectin-binding integrin sub-
units might have been affected by plakoglobin silencing.
Since IPF is a fibroproliferative disease, and the level
of proliferative capacity of activated fibroblasts may be
increased in IPF patients [40], we sought to determine
whether abnormal plakoglobin expression altered the
proliferative response to PDGF or TGF-β in normal and
IPF fibroblasts. While we did not observe an effect of
plakoglobin silencing on fibroblast proliferation, our
data appear to be in agreement with a second study
showing no difference in proliferation in plakoglobin-null
keratinocytes [29]. Together these data seem to suggest
Fig. 6 PARP expression analysis in plakoglobin knockdown in IPF
fibroblasts. Representative western blots that were successfully
silenced for plakoglobin (upper panel, right 3 lanes) compared to
the control treated cells (left 3 lanes). Cleaved PARP (116 kDa and
89 kDa) (lower panel) in IPF fibroblasts was assessed in cells treated
with (+) or without (−) anti-FasL/Cyclo. GAPDH was used as a
loading control
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that neither baseline nor PDGF-stimulated proliferation is
dependent on plakoglobin. The lack of response to PDGF
in the IPF fibroblasts is consistent with several prior re-
ports [41–43]. A study on IPF fibroblast proliferation has
made it clear that the location and age of the IPF fibro-
blasts will affect the proliferative rate of the cells [41].
Usual interstitial pneumonia, the histologic hallmark of
IPF, is a highly heterogeneous injury pattern where highly
fibrotic areas can be adjacent to normal tissue. Thus, sam-
pling lung fibroblasts using a standard explant method
may account for variations in fibroblast behavior seen in
our study.
One of the hallmarks of IPF is an overabundance of
myofibroblasts localized to areas of active matrix synthe-
sis termed fibroblastic foci. Staining fibroblastic foci in
IPF tissue revealed that the epithelium and not the
Fig. 7 Cleaved PARP protein expression and cell viability in normal and IPF fibroblasts. Transfected normal (a, c) and IPF (b, d) fibroblasts were
treated with (+) or without (−) anti-FasL and cycloheximide for 6 hours (A and B). Results indicate that at 6 hours, the normal (Φ-siRNA (−/−),
n = 13, Φ-siRNA (+/+), n = 16, siRNA-PG (−/−), n = 15 and siRNA-PG (+/+), n = 12) (a) and IPF (Φ-siRNA (−/−), n = 8, Φ-siRNA (+/+), n = 7, siRNA-PG
(−/−), n = 7 and siRNA-PG (+/+), n = 4) (b) fibroblasts transfected with ɸsiRNA or siRNA-PG and treated (+/+) had significantly higher levels of
cleaved PARP compared to the transfected cells not treated (−/−) (p < 0.0003, p < 0.0002, p < 0.003 and p < 0.01, respectively). (a). There was no
significance found between the ɸsiRNA and siRNA-PG experimental groups in either normal or IPF fibroblasts. PI levels were assessed by flow
cytometry after overnight treatment with (+) or without (−) anti-FasL/cycloheximide in normal and IPF fibroblasts (c and d). The normal transfected
fibroblasts did not show any significant change in PI positivity between the treated (+/+) and untreated (−/−) transfected cells (Φ-siRNA (−/−), n = 7,
Φ-siRNA (+/+), n = 8, siRNA-PG (−/−), n = 6 and siRNA-PG (+/+), n = 8) (c). The IPF fibroblasts did show a significant difference between the treated
(+/+) and untreated (−/−) transfection groups (ɸsiRNA or siRNA-PG, p< 0.05 and p < 0.005, respectively). However, there is a lack of significance between
the ɸsiRNA and siRNA-PG groups treated with anti-FasL/Cyclo (+/+) (Φ-siRNA (−/−), n = 7, Φ-siRNA (+/+), n = 7, siRNA-PG (−/−), n = 7 and
siRNA-PG (+/+), n = 7) (d)
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myofibroblasts express apoptotic markers [40]. This is
supported by other studies that suggest IPF myofibro-
blasts are more resistant to Fas-induced apoptosis [31,
44, 45]. Research findings propose that plakoglobin plays
a role in regulating cellular survival. Two separate stud-
ies using keratinocytes with a reduced level of plakoglo-
bin demonstrated both a decrease in cell-cell contact
and a reduction in apoptosis [29, 46]. Other studies sug-
gest that plakoglobin increases the likelihood of a cell to
undergo apoptosis, whereas without endogenous plako-
globin the cells are unable to release cytochrome c from
the mitochondria and therefore are deficient in activat-
ing caspase-3 in response to apoptotic stimuli [29, 30].
Thus, we hypothesized that decreased plakoglobin ex-
pression seen in IPF fibroblasts might account for the
relative resistance to apoptosis. On the contrary, our
results did not indicate any significant difference in the
expression of apoptotic markers cleaved PARP (Figs. 6
and 7, panels a and b) or propidium iodide (Fig. 7, panels
c and d) between normal and IPF fibroblasts when PG
was silenced with siRNA. However, it is possible that cells
with low plakoglobin are resistant to apoptosis from other
stimuli; this hypothesis will require further testing.
Our knockdown efficiency for plakoglobin was ap-
proximately 80 % (Fig. 3). There may be more robust
differences in phenotypic behavior of fibroblasts that have
PG protein expression completely eradicated. Further
studies using a construct to effectively knockout PG would
be the next series of experiments to pursue. Despite these
results, the down regulation of plakoglobin in IPF lung
fibroblasts may well have other, as yet unidentified, effects
on cellular behavior and/or disease progression. Our data
suggest that further study into the role of plakoglobin in
IPF is warranted to identify a functional consequence of
the observed decreased protein expression.
Conclusions
In summary, previous studies suggest that plakoglobin
affects cell-cell and cell-matrix interactions in various sys-
tems. However, our data indicate that plakoglobin may not
have a similar effect in healthy or diseased lung fibroblasts.
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